Latest FDA-Approved Preventive Treatment For Migraine, Qulipta, Enters A Highly Competitive Market

On September 28th, the FDA approved a once-daily oral medicine, Qulipta (atogepant), for preventive treatment of episodic migraine in adults. It is the second FDA-approved, oral anti-CGRP drug for preventing migraine. The first was Nurtec ODT (rimegepant).

Source: Forbes.com Healthcare News - October 3, 2021 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news